Fulgent Genetics (FLGT) Share-based Compensation (2015 - 2026)

Fulgent Genetics has reported Share-based Compensation for 12 years, with the latest figure at $8.6 million in Q2 2026.

• Quarterly Share-based Compensation fell 14.1% year-over-year to $8.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.5 million (down 10.52% YoY) and the FY2025 annual result came in at $39.6 million, down 11.01% from the prior year.
• Share-based Compensation declined to $8.6 million in Q2 2026 per FLGT's latest filing, from $9.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $11.6 million in Q2 2024 and troughed at $5.6 million in Q1 2022.
• A 5-year average of $9.9 million and a median of $10.2 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation surged 127.74% in 2022, then slipped 14.1% in 2026.
• Over 5 years, Share-based Compensation stood at $10.0 million in 2022, then advanced by 14.07% to $11.4 million in 2023, then dropped by 8.96% to $10.4 million in 2024, then dropped by 10.88% to $9.3 million in 2025, then dropped by 7.03% to $8.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $8.6 million, $9.9 million, and $9.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.